Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis

The aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina.

Guardado en:
Detalles Bibliográficos
Autores principales: Kanevsky, Diego, Elgart, Jorge Federico, Zerga, Marta, Glancszpigel, Mariana, Morisset, Pierre
Formato: Articulo
Lenguaje:Inglés
Publicado: 2022
Materias:
Ciencias Médicas
venetoclax plus obinutuzumab
lymphocytic leukemia
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/156981
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-156981
record_format dspace
spelling I19-R120-10915-1569812023-08-29T20:40:42Z http://sedici.unlp.edu.ar/handle/10915/156981 Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis Kanevsky, Diego Elgart, Jorge Federico Zerga, Marta Glancszpigel, Mariana Morisset, Pierre 2022-06 2023-08-29T13:33:59Z en Ciencias Médicas venetoclax plus obinutuzumab lymphocytic leukemia The aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina. XXVII Congress of the European Hematology Association (Viena, 9 al 17 de junio de 2022) Centro de Endocrinología Experimental y Aplicada Articulo Articulo http://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) application/pdf 3004-3005
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
venetoclax plus obinutuzumab
lymphocytic leukemia
spellingShingle Ciencias Médicas
venetoclax plus obinutuzumab
lymphocytic leukemia
Kanevsky, Diego
Elgart, Jorge Federico
Zerga, Marta
Glancszpigel, Mariana
Morisset, Pierre
Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
topic_facet Ciencias Médicas
venetoclax plus obinutuzumab
lymphocytic leukemia
description The aim of the study was to estimate the cost-effectiveness of VenG in the treatment of first-line unfit CLL patients in Argentina.
format Articulo
Articulo
author Kanevsky, Diego
Elgart, Jorge Federico
Zerga, Marta
Glancszpigel, Mariana
Morisset, Pierre
author_facet Kanevsky, Diego
Elgart, Jorge Federico
Zerga, Marta
Glancszpigel, Mariana
Morisset, Pierre
author_sort Kanevsky, Diego
title Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
title_short Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
title_full Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
title_fullStr Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
title_full_unstemmed Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis
title_sort venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in argentina: a cost-effectiveness analysis
publishDate 2022
url http://sedici.unlp.edu.ar/handle/10915/156981
work_keys_str_mv AT kanevskydiego venetoclaxincombinationwithobinutuzumabinfirstlinechroniclymphocyticleukemiainargentinaacosteffectivenessanalysis
AT elgartjorgefederico venetoclaxincombinationwithobinutuzumabinfirstlinechroniclymphocyticleukemiainargentinaacosteffectivenessanalysis
AT zergamarta venetoclaxincombinationwithobinutuzumabinfirstlinechroniclymphocyticleukemiainargentinaacosteffectivenessanalysis
AT glancszpigelmariana venetoclaxincombinationwithobinutuzumabinfirstlinechroniclymphocyticleukemiainargentinaacosteffectivenessanalysis
AT morissetpierre venetoclaxincombinationwithobinutuzumabinfirstlinechroniclymphocyticleukemiainargentinaacosteffectivenessanalysis
_version_ 1807221129202368512

Ejemplares similares